Premium
Abuse potential of zomepirac
Author(s) -
Johnson Rolley E,
Jasinski Donald R,
Kocher Theresa R
Publication year - 1983
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1983.184
Subject(s) - morphine , placebo , analgesic , clinical pharmacology , pharmacology , medicine , nonsteroidal , population , anesthesia , alternative medicine , pathology , environmental health
Zomepirac sodium, a nonsteroidal anti‐inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800‐mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused. Clinical Pharmacology and Therapeutics (1983) 34 , 386–389; doi: 10.1038/clpt.1983.184